Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance
Plus: Japan Passes Bill For Free Vaccines
Executive Summary
Swiss biotech Molecular Partners will receive upfront payment of CHF60m, including equity.
You may also be interested in...
Novartis Steps Up To Plate To Produce Pfizer/BioNTech COVID-19 Vaccine
In the latest example of cross-industry collaboration in these turbulent times, Novartis is joining forces with Pfizer and BioNTech to help produce their in-demand mRNA vaccine at a facility in Switzerland.
Novartis’s JAK Inhibitor Fails In COVID, Raising Questions On Lilly Prospects
The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.
Novartis’s Canakinumab Fails In COVID-19 Pneumonia Patients
Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports